Cure8 research brief
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
Patients on vedolizumab (especially those on subcutaneous maintenance), clinicians who manage biologic dosing, and researchers studying therapeutic‑drug‑monitoring and dosing strategies.
This is a population pharmacokinetic (popPK) analysis using real‑world data from 61 patients (43 Crohn’s disease, 18 ulcerative colitis) with 225 serum samples. The authors developed a two‑compartment model with linear and nonlinear elimination and found that clearance varied with body weight, albumin, and white blood cell count.
Using model simulations, they estimated that a minority of patients with higher trough concentrations on SC Q2W dosing might maintain troughs ≥26 mg/L if de‑escalated to Q3W (about 18% of patients) or Q4W (about 2%). The authors emphasize that prospective clinical studies are needed to confirm safety and effectiveness of such de‑escalation.
Keep the focus on what the paper reports: PK modeling and simulation rather than clinical outcomes. This abstract does not report clinical relapse rates or patient outcomes after dose spacing changes.
This report is a popPK modeling and simulation study (abstract-level content). It uses real‑world PK samples but does not provide clinical outcome data on relapse or remission after dose de‑escalation—prospective trials are required before changing practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
